Maintaining one’s creative identity can be challenging when working in technical and corporate environments. This was especially true for Ty Hall, whose creativity suffered under the constant yet ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

GreenSinnergy GmbH (Tübingen, Germany), a company specialized in green project developments, and Axens (Rueil-Malmaison, France), a global provider of ...

The guidelines include disease-specific recommendations on screening, monitoring disease progression, and treatment options ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

Germany plans to make its faulty railway network its first priority as it seeks to fast-track spending from its €500bn infrastructure fund designed to lift Europe’s largest economy out of stagnation.

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, the companies said Thursday, bringing together two ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

The plan is to bring the two biotech companies together to develop transformative cancer treatments, BioNTech said.

CureVac (CVAC) stock jumps as BioNTech (BNTX) agrees to acquire in an all-stock deal worth $1.25B. Read more here.